Literature DB >> 28644097

Thirty-day postoperative morbidity and mortality after temporal lobectomy for medically refractory epilepsy.

Panagiotis Kerezoudis1,2, Brandon McCutcheon1,2, Meghan E Murphy1,2, Kenan R Rajjoub3, Daniel Ubl4, Elizabeth B Habermann4, Gregory Worrell5, Mohamad Bydon1,2, Jamie J Van Gompel1.   

Abstract

OBJECTIVE Temporal lobectomy is a well-established treatment modality for the management of medically refractory epilepsy in appropriately selected patients. The aim of this study was to assess 30-day morbidity and mortality after temporal lobectomy in cases registered in a national database. METHODS A retrospective cohort analysis was conducted using a multiinstitutional surgical registry compiled between 2006 and 2014. The authors identified patients who underwent anterior temporal lobectomy and/or amygdalohippocampectomy for a primary diagnosis of intractable epilepsy. Univariate and multivariable analyses with regard to patient demographics, comorbidities, operative characteristics, and 30-day outcomes were applied. RESULTS A total of 216 patients were included in the study. The median age was 38 years and 46% of patients were male. The median length of stay was 3 days and the 30-day mortality rate was 1.4%. Fourteen patients (6.5%) developed at least one major complication. Return to the operating room was observed in 7 patients (3.2%). Readmission within 30 days and discharge to a location other than home were available for 2011-2014 (n = 155) and occurred in 11% and 10.3% of patients, respectively. Multivariable regression analysis revealed that increasing age was an independent predictor of discharge disposition other than home and that male sex was a significant risk factor for the development of a major complication. Interestingly, the presence of the attending neurosurgeon and a resident during the procedure was significantly associated with decreased odds of prolonged length of stay (i.e., > 75th percentile [5 days]) and discharge to a location other than home. CONCLUSIONS Using a multiinstitutional surgical registry, 30-day outcome data after temporal lobectomy for medically intractable epilepsy demonstrates a mortality rate of 1.4%, a major complication rate of 6.5%, and a readmission rate of 11%. Temporal lobectomy is an extremely effective therapy for seizures originating there-however, surgical intervention must be weighed against its morbidity and mortality outcomes.

Entities:  

Keywords:  9th Revision; ACS = American College of Surgeons; ASA = American Society of Anesthesiologists; ASM = antiseizure medication; ATL = anterior temporal lobectomy; BMI = body mass index; CPT = Current Procedural Terminology; DVT = deep vein thrombosis; ICD-9 = International Classification of Diseases; LOS = length of stay; MI = myocardial infarction; NIS = Nationwide Inpatient Sample; NSQIP; NSQIP = National Surgical Quality Improvement Program; National Surgical Quality Improvement Program; PUF = Participant User File; TLE = temporal lobe epilepsy; UTI = urinary tract infection; amygdalohippocampectomy; epilepsy surgery; temporal lobectomy

Mesh:

Year:  2017        PMID: 28644097     DOI: 10.3171/2016.12.JNS162096

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

Review 1.  The current place of epilepsy surgery.

Authors:  Jerome Engel
Journal:  Curr Opin Neurol       Date:  2018-04       Impact factor: 5.710

2.  Sex-related differences in postoperative complications following elective craniotomy for intracranial lesions: An observational study.

Authors:  Giovanna Brandi; Vittorio Stumpo; Marco Gilone; Lazar Tosic; Johannes Sarnthein; Victor E Staartjes; Sophie Shih-Yüng Wang; Bas Van Niftrik; Luca Regli; Emanuela Keller; Carlo Serra
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

3.  Assessment of Gender Disparities in Short-Term and Long-Term Outcomes Following Posterior Fossa Tumor Resection.

Authors:  Ali S Farooqi; Starr Jiang; Austin J Borja; Donald K E D Detchou; Ryan Dimentberg; Kaitlyn Shultz; Scott D McClintock; Neil R Malhotra
Journal:  Cureus       Date:  2021-11-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.